National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 4) (No. PB 33 of 2012) (Cth)

Case
No judgment structure available for this case.

PB 33 of 2012

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012
(No.4)1

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 4 May 2012

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

1          Name of Instrument

(1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 4).

(2)        This Instrument may also be cited as PB 33 of 2012.

2          Commencement

This Instrument commences on 1 June 2012.

3          Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010)

Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (PB 108 of 2010).

Schedule 1     Amendments

[1]Schedule 1, entry for Amlodipine with Atorvastatin

substitute:

Amlodipine with Atorvastatin Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) Oral Cadatin 5/10 FZ MP NP C2449 C2450 C2451 30 5
Caduet 5/10 PF MP NP C2449 C2450 C2451 30 5
Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) Oral Cadatin 5/20 FZ MP NP C2449 C2450 C2451 30 5
Caduet 5/20 PF MP NP C2449 C2450 C2451 30 5
Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) Oral Cadatin 5/40 FZ MP NP C2449 C2450 C2451 30 5
Caduet 5/40 PF MP NP C2449 C2450 C2451 30 5
Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) Oral Cadatin 5/80 FZ MP NP C2449 C2450 C2451 30 5
Caduet 5/80 PF MP NP C2449 C2450 C2451 30 5
Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium) Oral Cadatin 10/10 FZ MP NP C2449 C2450 C2451 30 5
Caduet 10/10 PF MP NP C2449 C2450 C2451 30 5
Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium) Oral Cadatin 10/20 FZ MP NP C2449 C2450 C2451 30 5
Caduet 10/20 PF MP NP C2449 C2450 C2451 30 5
Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium) Oral Cadatin 10/40 FZ MP NP C2449 C2450 C2451 30 5
Caduet 10/40 PF MP NP C2449 C2450 C2451 30 5
Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium) Oral Cadatin 10/80 FZ MP NP C2449 C2450 C2451 30 5
Caduet 10/80 PF MP NP C2449 C2450 C2451 30 5

[2]Schedule 1, entry for Amoxycillin

omit:

Sachet containing oral powder 3 g (as trihydrate) Oral Amoxil GK MP NP PDP 1 0

[3]Schedule 1, entry for Anastrozole in the form Tablet 1 mg

omit:

Anastrozole LW TA MP NP C2213 30 5

[4]Schedule 1, entry for Atorvastatin

substitute:

Atorvastatin Tablet 10 mg (as calcium) Oral APO-Atorvastatin TX MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvachol GM MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin GH GQ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Pfizer FZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Chem mart Atorvastatin CH MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lipitor PF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lorstat 10 AF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Terry White Chemists Atorvastatin TW MP C1540 C3047 P1540 30 5
NP C1540 30 5
Torvastat 10 QA MP C1540 C3047 P1540 30 5
NP C1540 30 5
Trovas RA MP C1540 C3047 P1540 30 5
NP C1540 30 5
APO-Atorvastatin TX MP C1540 C3047 P3047 30 11
Atorvachol GM MP C1540 C3047 P3047 30 11
Atorvastatin GH GQ MP C1540 C3047 P3047 30 11
Atorvastatin Pfizer FZ MP C1540 C3047 P3047 30 11
Atorvastatin Sandoz SZ MP C1540 C3047 P3047 30 11
Chem mart Atorvastatin CH MP C1540 C3047 P3047 30 11
Lipitor PF MP C1540 C3047 P3047 30 11
Lorstat 10 AF MP C1540 C3047 P3047 30 11
Terry White Chemists Atorvastatin TW MP C1540 C3047 P3047 30 11
Torvastat 10 QA MP C1540 C3047 P3047 30 11
Trovas RA MP C1540 C3047 P3047 30 11
Tablet 20 mg (as calcium) Oral APO-Atorvastatin TX MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvachol GM MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin GH GQ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Pfizer FZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Chem mart Atorvastatin CH MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lipitor PF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lorstat 20 AF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Terry White Chemists Atorvastatin TW MP C1540 C3047 P1540 30 5
NP C1540 30 5
Torvastat 20 QA MP C1540 C3047 P1540 30 5
NP C1540 30 5
Trovas RA MP C1540 C3047 P1540 30 5
NP C1540 30 5
APO-Atorvastatin TX MP C1540 C3047 P3047 30 11
Atorvachol GM MP C1540 C3047 P3047 30 11
Atorvastatin GH GQ MP C1540 C3047 P3047 30 11
Atorvastatin Pfizer FZ MP C1540 C3047 P3047 30 11
Atorvastatin Sandoz SZ MP C1540 C3047 P3047 30 11
Chem mart Atorvastatin CH MP C1540 C3047 P3047 30 11
Lipitor PF MP C1540 C3047 P3047 30 11
Lorstat 20 AF MP C1540 C3047 P3047 30 11
Terry White Chemists Atorvastatin TW MP C1540 C3047 P3047 30 11
Torvastat 20 QA MP C1540 C3047 P3047 30 11
Trovas RA MP C1540 C3047 P3047 30 11
Tablet 40 mg (as calcium) Oral APO-Atorvastatin TX MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvachol GM MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin GH GQ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Pfizer FZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Chem mart Atorvastatin CH MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lipitor PF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lorstat 40 AF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Terry White Chemists Atorvastatin TW MP C1540 C3047 P1540 30 5
NP C1540 30 5
Torvastat 40 QA MP C1540 C3047 P1540 30 5
NP C1540 30 5
Trovas RA MP C1540 C3047 P1540 30 5
NP C1540 30 5
APO-Atorvastatin TX MP C1540 C3047 P3047 30 11
Atorvachol GM MP C1540 C3047 P3047 30 11
Atorvastatin GH GQ MP C1540 C3047 P3047 30 11
Atorvastatin Pfizer FZ MP C1540 C3047 P3047 30 11
Atorvastatin Sandoz SZ MP C1540 C3047 P3047 30 11
Chem mart Atorvastatin CH MP C1540 C3047 P3047 30 11
Lipitor PF MP C1540 C3047 P3047 30 11
Lorstat 40 AF MP C1540 C3047 P3047 30 11
Terry White Chemists Atorvastatin TW MP C1540 C3047 P3047 30 11
Torvastat 40 QA MP C1540 C3047 P3047 30 11
Trovas RA MP C1540 C3047 P3047 30 11
Tablet 80 mg (as calcium) Oral APO-Atorvastatin TX MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvachol GM MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin GH GQ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Pfizer FZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Atorvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5
Chem mart Atorvastatin CH MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lipitor PF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Lorstat 80 AF MP C1540 C3047 P1540 30 5
NP C1540 30 5
Terry White Chemists Atorvastatin TW MP C1540 C3047 P1540 30 5
NP C1540 30 5
Torvastat 80 QA MP C1540 C3047 P1540 30 5
NP C1540 30 5
Trovas RA MP C1540 C3047 P1540 30 5
NP C1540 30 5
APO-Atorvastatin TX MP C1540 C3047 P3047 30 11
Atorvachol GM MP C1540 C3047 P3047 30 11
Atorvastatin GH GQ MP C1540 C3047 P3047 30 11
Atorvastatin Pfizer FZ MP C1540 C3047 P3047 30 11
Atorvastatin Sandoz SZ MP C1540 C3047 P3047 30 11
Chem mart Atorvastatin CH MP C1540 C3047 P3047 30 11
Lipitor PF MP C1540 C3047 P3047 30 11
Lorstat 80 AF MP C1540 C3047 P3047 30 11
Terry White Chemists Atorvastatin TW MP C1540 C3047 P3047 30 11
Torvastat 80 QA MP C1540 C3047 P3047 30 11
Trovas RA MP C1540 C3047 P3047 30 11

[5]Schedule 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Biso 2.5 WQ MP NP C3234 28 5

[6]Schedule 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Biso 5 WQ MP NP C3234 28 5

[7]Schedule 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Biso 10 WQ MP NP C3234 28 5

[8]Schedule 1, entry for Carvedilol in the form Tablet 3.125 mg

(a)        omit:

Dilasig 3.125 FM MP NP C1735 C3234 30 0

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Volirop 3.125 DO MP NP C1735 C3234 30 0

[9]Schedule 1, entry for Carvedilol in the form Tablet 6.25 mg

(a)        omit:

Dilasig 6.25 FM MP NP C1735 C3234 60 5

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Volirop 6.25 DO MP NP C1735 C3234 60 5

[10]Schedule 1, entry for Carvedilol in the form Tablet 12.5 mg

(a)        omit:

Dilasig 12.5 FM MP NP C1735 C3234 60 5

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Volirop 12.5 DO MP NP C1735 C3234 60 5

[11]Schedule 1, entry for Carvedilol in the form Tablet 25 mg

(a)        omit:

Dilasig 25 FM MP NP C1735 C3234 60 5

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Volirop 25 DO MP NP C1735 C3234 60 5

[12]Schedule 1, entry for Cephazolin in each of the forms: Powder for injection 500 mg (as sodium); and Powder for injection 1 g (as sodium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Cefazolin-AFT AE MP NP C1169 C1846 C1847 C3132 10 0

[13]Schedule 1, entry for Diltiazem in the form Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg

(a)        omit from the column headed “Responsible Person” for the brand “Diltahexal CD”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Diltiazem Sandoz CD SZ MP NP 30 5

[14]Schedule 1, entry for Fluconazole

omit:

Fluzole 50 QA MP NP C3613 C3614 C3615 C3616 C3617 C3618 28 5

[15]Schedule 1, entry for Fosinopril in each of the forms: Tablet containing fosinopril sodium 10 mg; and Tablet containing fosinopril sodium 20 mg

omit:

Fosinopril Sandoz SZ MP NP 30 5

[16]Schedule 1, entry for Fosinopril with Hydrochlorothiazide in the form Tablet containing fosinopril sodium 10 mg with hydrochlorothiazide 12.5 mg

omit:

Fosinopril/HCT Sandoz 10mg/12.5mg SZ MP NP C3307 30 5

[17]Schedule 1, entry for Fosinopril with Hydrochlorothiazide in the form Tablet containing fosinopril sodium 20 mg with hydrochlorothiazide 12.5 mg

omit:

Fosinopril/HCT Sandoz 20mg/12.5mg SZ MP NP C3307 30 5

[18]Schedule 1, entry for Gemcitabine in each of the forms: Powder for I.V. infusion 200 mg (as hydrochloride); and Powder for I.V. infusion 1 g (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Gemaccord WQ MP See Note 3 See Note 3 D

[19]Schedule 1, after entry for Glucose Indicator—Blood in the form Test strips, 100 (Accu-Chek Performa)

insert:

Test strips, 100 (Contour) For external use Contour IK MP NP 1 5
MP P3035 1 11

[20]Schedule 1, entry for Irinotecan in each of the forms: I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL; and
I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Irinoccord WQ MP C3184 See Note 3 See Note 3 D

[21]Schedule 1, entry for Lamotrigine in the form Tablet 25 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Torlemo DT 25 TA MP NP C1426 56 5

[22]Schedule 1, entry for Lamotrigine in the form Tablet 50 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Torlemo DT 50 TA MP NP C1426 56 5

[23]Schedule 1, entry for Lamotrigine in the form Tablet 100 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Torlemo DT 100 TA MP NP C1426 56 5

[24]Schedule 1, entry for Lamotrigine in the form Tablet 200 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Torlemo DT 200 TA MP NP C1426 56 5

[25]Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg [Max Quantity 300; Number of Repeats 3]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pharmacor Mycophenolate 250 CR MP C1765 C1766 300 3

[26]Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg [Max Quantity 600; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Pharmacor Mycophenolate 250 CR MP
See Note 1 		C1650 C1651 C3355 C3356 600 5 C

[27]Schedule 1, entry for Oxaliplatin in each of the forms: Solution concentrate for I.V. infusion 50 mg in 10 mL; and Solution concentrate for I.V. infusion 100 mg in 20 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Oxaliccord

WQ

MP

C3900 C3901 C3930 C3939

See Note 3

See Note 3

D

[28]Schedule 1, entry for Paroxetine in the form Tablet 20 mg (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Roxet 20 DO MP NP C1211 C1241 C1862 30 5

[29]Schedule 1, entry for Paroxetine in the form Tablet 20 mg (as mesilate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Paroxetine Synthon ZT MP NP C1211 C1241 C1862 30 5

[30]Schedule 1, entry for Simvastatin in the form Tablet 5 mg [Max Quantity 30; Number of Repeats 5]

(a)        omit from the column headed “Responsible Person” for the brand “Simvahexal”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Simvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5

[31]Schedule 1, entry for Simvastatin in the form Tablet 5 mg [Max Quantity 30; Number of Repeats 11]

(a)        omit from the column headed “Responsible Person” for the brand “Simvahexal”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Simvastatin Sandoz SZ MP C1540 C3047 P3047 30 11

[32]Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 5]

(a)        omit from the column headed “Responsible Person” for the brand “Simvahexal”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Simvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5

[33]Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 11]

(a)        omit from the column headed “Responsible Person” for the brand “Simvahexal”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Simvastatin Sandoz SZ MP C1540 C3047 P3047 30 11

[34]Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 5]

(a)        omit from the column headed “Responsible Person” for the brand “Simvahexal”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Simvastatin Sandoz SZ MP C1540 C3047 P1540 30 5
NP C1540 30 5

[35]Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 11]

(a)        omit from the column headed “Responsible Person” for the brand “Simvahexal”:   SZ          substitute:                HX

(b)          insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Simvastatin Sandoz SZ MP C1540 C3047 P3047 30 11

[36]Schedule 1, after entry for Tenofovir with emtricitabine and efavirenz

insert:

Tenofovir with Emtricitabine and Rilpivirine Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg and rilpivirine 25 mg (as hydrochloride) Oral Eviplera GI MP
See Note 1 		C3983 C3984 C3985 C3986 60 5 D

[37]Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 20; Number of Repeats 0]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Valaciclovir Pfizer FZ MP NP C3622 C3623 C3624 C3631 C3632 P3632 20 0

[38]Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 30; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Valaciclovir Pfizer FZ MP NP C3622 C3623 C3624 C3631 C3632 P3623 P3624 30 5

[39]Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride) [Max Quantity 42; Number of Repeats 0]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Valaciclovir Pfizer FZ MP NP C3622 C3623 C3624 C3631 C3632 P3622 P3631 42 0

[40]      Schedule 3, after details relevant to Responsible person code IA

insert:

IK Medtronic Australasia Pty Ltd 47 001 162 661

[41]      Schedule 4, Part 1, after entry for Tenofovir with emtricitabine and efavirenz

insert:

Tenofovir with Emtricitabine and Rilpivirine C3983

Where the patient is receiving treatment at/from a private hospital

Initial treatment of human immunodeficiency virus (HIV) infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

 Compliance with Written or Telephone Authority Required procedures
C3984

Where the patient is receiving treatment at/from a private hospital

Continuing treatment of human immunodeficiency virus (HIV) infection where the patient has previously received PBS-subsidised therapy for HIV infection

 Compliance with Written or Telephone Authority Required procedures
C3985

Where the patient is receiving treatment at/from a public hospital

Initial treatment of human immunodeficiency virus (HIV) infection in a patient with a CD4 count of less than 500 per cubic millimetre or symptomatic HIV disease

 Compliance with Written or Telephone Authority Required procedures Streamlined Authority Code 3985
C3986

Where the patient is receiving treatment at/from a public hospital

Continuing treatment of human immunodeficiency virus (HIV) infection where the patient has previously received PBS-subsidised therapy for HIV infection

 Compliance with Written or Telephone Authority Required procedures - Streamlined Authority Code 3986

1

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.

See

Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0